Plastic bottles turned into Parkinson’s drug

March 16, 2026

Scientists at the University of Edinburgh have genetically modified E. coli bacteria to convert polyethylene terephthalate (PET)—a common plastic used in food and beverage packaging—into L-DOPA (levodopa), the gold-standard medication for managing Parkinson’s symptoms.

Each year, approximately 50 million tonnes of PET plastic are produced globally, contributing significantly to environmental pollution. The new process begins by breaking down PET waste into its core chemical component, terephthalic acid. Through a series of carefully engineered biological reactions, the modified bacteria transform this compound into pharmaceutical-grade L-DOPA.

This innovative biomanufacturing approach replaces fossil fuel–dependent chemical synthesis with a renewable, biology-based production system, making it a more environmentally sustainable method for drug manufacturing.

Sustainable pharmaceutical production from plastic waste

Traditional pharmaceutical manufacturing often relies on non-renewable resources such as oil and gas. In contrast, this new bio-upcycling technology uses waste plastic as a carbon source, reducing reliance on finite materials while lowering environmental impact.

Recycling PET remains a global challenge. Although mechanical recycling exists, it is inefficient and does not eliminate plastic pollution. The Edinburgh team’s solution not only diverts plastic from landfills and incinerators but also upgrades it into a high-value medical product.

Beyond Parkinson’s treatment, this breakthrough could fuel the growth of a bio-upcycling industry capable of producing:

• Pharmaceuticals

• Flavorings and fragrances

• Cosmetic ingredients

• Specialty and industrial chemicals

By transforming waste into valuable commodities, the technology supports a circular economy and advances green manufacturing.

Scaling up the technology for industrial use

After successfully producing and isolating L-DOPA at preparative scale, researchers are now focusing on:

• Enhancing process efficiency

• Improving scalability for industrial production

• Evaluating environmental performance

• Assessing economic viability

The findings were published in Nature Sustainability, underscoring the global significance of the research.

The carbon-loop sustainable biomanufacturing hub (C-Loop)

The project was developed within the £14 million Carbon-Loop Sustainable Biomanufacturing Hub (C-Loop), a cutting-edge initiative designed to convert industrial waste into sustainable chemicals and materials. The hub is funded by the Engineering and Physical Sciences Research Council (EPSRC), part of UK Research and Innovation (UKRI).

Commercialization support is provided by Edinburgh Innovations, which works to bring university research into industry applications.

Leaders involved in the project emphasize that this technology could spark a green revolution in UK manufacturing, helping industries reduce carbon footprints while producing high-value products.

Engineering biology: redesigning waste into wellness

The study highlights the growing impact of engineering biology in solving environmental and healthcare challenges simultaneously. By demonstrating that plastic pollution can be converted into a life-changing medication for Parkinson’s disease, the research reshapes how society views waste.

Rather than being a purely environmental burden, plastic represents a vast and underutilized carbon resource. Through advanced microbial engineering, that carbon can now be redirected into sustainable pharmaceutical production.

As the technology advances toward commercialization, it could redefine how medicines are made—turning everyday plastic bottles into critical treatments that improve human health while protecting the planet.